Insights
Search Results
Client Highlights
4.17.26
Firm Advises Neurona Therapeutics on Acquisition by UCB
On April 17, 2026, UCB, a global biopharmaceutical company, announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Therapeutics is a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for epilepsies and other disorders of the nervous system. Under the terms of the agreement, UCB will pay $650 million upfront and up to $500 million in potential future milestone payments, subject to certain closing conditions. Wilson Sonsini Goodrich & Rosati advised Neurona on the transaction.
Client Highlights
4.08.26
Wilson Sonsini Advises Sidewinder Therapeutics on Oversubscribed $137 Million Series B Financing
On April 8, 2026, Sidewinder Therapeutics, a biopharmaceutical company pioneering the development of next-generation bispecific antibody-drug conjugates (ADCs) for the treatment of cancer, announced the closing of an oversubscribed $137 million Series B financing. The round was co-led by Frazier Life Sciences and Novartis Venture Fund, with participation from the sole Series A investor OrbiMed, as well as new investors including Life Sciences at Goldman Sachs Alternatives, DCVC Bio, Samsara BioCapital, Longwood Fund, Astellas Venture Management, and Alexandria Venture Investments. Wilson Sonsini Goodrich & Rosati advised Sidewinder Therapeutics on the transaction.
Client Highlights
12.17.25
Wilson Sonsini Advises Hexagon Bio on Multimillion-Dollar Joint Venture with Corteva
On December 16, 2025, Corteva, a global leader in agricultural technology, and Hexagon Bio, a biotechnology company pioneering a new way to discover nature-derived medicine, announced a multimillion-dollar joint venture (JV) to accelerate the development of new crop protection solutions inspired by nature. The JV is the first in the agriculture sector for Hexagon Bio and the first in the pharmaceutical industry for Corteva. Wilson Sonsini Goodrich & Rosati advised Hexagon Bio on the transaction.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
The partnership brings together Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform to advance the companies’ respective pipelines across agriculture and human health. Hexagon Bio’s platform combines microbial genetics, artificial intelligence, chemistry, and synthetic biology to identify and characterize novel natural products, uncovering diverse mechanisms not obvious from the chemical structure or conventional techniques and allowing for more efficient molecule discovery.
The Wilson Sonsini team that advised Hexagon Bio on the transaction included Ken Clark, Norm Hovijitra, Aleks Vitomirov, Lance Brady, Christina Poulsen, Adrian Broderick, Sara Pollock, Jacob Morales, Henry Yen, Myra Sutanto Shen, and Rob Sherrill.
For more information, please see the companies’ joint news release.
Client Highlights
5.06.25
Wilson Sonsini Advises Stately Bio on $12 Million Seed Financing
On May 2, 2025, Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from stealth with $12 million in seed financing. The funding was led by AIX Ventures, with participation from Dimension Capital, Foothill Ventures, Village Global, Caffeinated Capital, Mitsui Global Investment, BoxOne Ventures, Axial VC, Jeff Dean (Chief Scientist at Google DeepMind), Jeremy Wertheimer (co-founder of ITA Software), and Tom Berry (co-founder of Carbon Health). The new funding will be used to scale the company’s platform technology and mature its internal pipeline of stem cell-derived therapeutics.
Client Highlights
4.23.25
Wilson Sonsini Advises Synthetic Design Lab on $20 Million Seed Funding
On April 23, 2025, Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth with $20 million in seed financing. Playground Global and Godfrey Capital were among the investors in the funding round.
Client Highlights
4.08.25
Wilson Sonsini Advises Neurona Therapeutics on $102 Million Oversubscribed Financing
On April 3, 2025, Neurona Therapeutics, a clinical-stage, privately held biotherapeutics company developing regenerative cell therapies for disorders of the nervous system, announced the completion of an upsized and oversubscribed $102 million financing. Fidelity Management & Research Company, The Column Group, Soleus Capital, Viking Global Investors, Cormorant Asset Management, Schroders Capital, LYFE Capital, Euclidean Capital, UCB Ventures, Willett Advisors, UC Investments, YK Bioventures, Berkeley Frontier Fund, Ysios Capital, Alexandria Venture Investments, and Spur Capital Partners all participated in the financing round. Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction.
News Articles
8.08.24
IFLR1000 Recognizes Wilson Sonsini Practices, Attorneys in 2024 Guide
In the 2024 edition of its annual guide, IFLR recognized Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors in the U.S. and China. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.
Client Highlights
7.25.24
Wilson Sonsini Advises Dren Bio on Collaboration with Novartis
On July 24, 2024, Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune, and other serious diseases, announced that it has entered into a strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies for cancer using Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform. Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction.
Client Highlights
4.03.24
Wilson Sonsini Advises Alterome on $132 Million Series B
On April 3, 2024, Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, announced the closing of a $132 million Series B financing. The financing was led by Goldman Sachs Alternatives, with participation by Canaan Partners, Invus, Driehaus Capital Management, Digitalis Ventures, Blue Owl Capital, and existing investors Orbimed, Nextech Invest, Vida Ventures, Boxer Capital, and Colt Ventures. Wilson Sonsini Goodrich & Rosati advised Alterome on the transaction.
Client Highlights
2.20.24
Wilson Sonsini Advises Kinnate Biopharma on Acquisition By XOMA
On February 16, 2024, Kinnate Biopharma Inc., a clinical-stage precision oncology company, announced it has entered into a definitive merger agreement whereby XOMA Corporation will acquire Kinnate. Pursuant and subject to the terms of the merger agreement, a wholly owned subsidiary of XOMA will commence a tender offer by March 4, 2024 to acquire all outstanding shares of Kinnate common stock. The merger transaction is expected to close in the first half of 2024. Wilson Sonsini Goodrich & Rosati is advising Kinnate on the transaction.
Client Highlights
2.08.24
Wilson Sonsini Advises Neurona Therapeutics on $120 Million Financing
On February 8, 2024, Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, announced the completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participation from The Column Group, LYFE Capital, Schroders Capital, Willett Advisors, Ysios Capital Partners, Euclidean Capital, SymBiosis, Alexandria Venture Investments, Berkeley Frontier Fund, Sphera Biotech Master Fund LP, Spur Capital Partners, UCB Ventures, and UC Investments. Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction.
News Articles
8.01.23
Wilson Sonsini Practices and Attorneys Recognized in 2023 IFLR1000 Guide
In the recent 2023 edition of its annual guide, the IFLR1000 recognized numerous Wilson Sonsini practices and attorneys for their work in the financial and corporate sectors. The guide uses in-depth market analysis and interviews with practitioners and clients to determine leading financial and corporate law firms worldwide. Wilson Sonsini’s rankings are summarized below.